NCI IMAT R33 to advance and validate novel tools/methods that improve collection, handling, preservation, storage, and quality assessment of cancer biospecimens. Clinical trials not allowed
Eligibility Criteria
-
Eligible: higher-ed institutions; nonprofits; for-profits (incl. small businesses); government and tribal entities; foreign organizations
-
PD/PI must have an eRA Commons ID
-
Must include quantitative performance measures
-
Focus on technology advancement/validation (not hypothesis-driven biology)
Funding Details
-
Mechanism: R33 (Phase II)
-
Anticipated awards: ~2 (FY2026), total USD 900,000 (est.)
-
Budget: up to USD 300,000 direct costs/year
-
Project period: up to 3 years
-
Clinical trial: not allowed
-
FON: RFA-CA-25-004 (companions: RFA-CA-25-001/002/003)
Deadline
-
Due date: October 3, 2025 (5:00 PM local time)
Where to go for further information
-
Program contact: Kelly Crotty, Ph.D. ([email protected])